SecBot SecBot
SECBOTREPLAY Home › Report › TLX

TLX · Telix Pharmaceuticals completed enrollment of 350 patients in the Phase…

Telix Pharmaceuticals Ltd · 6-K filed Sep 1, 2026 at 20:30 ET

At the news

BULLISHIMPACT 7/10

6-K filed Sep 1, 2026 at 20:30 ET

Telix Pharmaceuticals completed enrollment of 350 patients in the Phase 3 BiPASS study of Illuccix and Gozellix for prostate cancer imaging in the pre-biopsy setting. The company also aligned with the FDA on an NDA pathway that, if approved, would support new product reimbursement and broaden patient access. This is a significant clinical milestone that could expand Telix's addressable market substantially if the study meets its primary objectives.

  • Completed enrollment of 350 patients in the Phase 3 BiPASS study
  • Aligned with FDA on an NDA pathway for BiPASS that would support new product reimbursement
  • BiPASS is the first registrational study of 68Ga-PSMA-PET imaging in the pre-biopsy setting
  • Prior PRIMARY and PRIMARY2 studies demonstrated combining PSMA-PET with MRI can reduce unnecessary biopsies by almost 50%

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access